Trial reportEndocrine2019
Effect of Nigella Sativa oil versus metformin on glycemic control and biochemical parameters of newly diagnosed type 2 diabetes mellitus patients.
Trial report in Endocrine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 6 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Pooled it
- Effect ofCurrent pharmaceutical biotechnology · 2024Pooled it
- The effect of Nigella sativa (black seed) on biomarkers of inflammation and oxidative stress: an updated systematic review and meta-analysis of randomized controlled trials.Inflammopharmacology · 2023Pooled it
- Pooled it
- Randomised controlled trials on prevention, diagnosis and treatment of diabetes in African countries: a systematic review.BMJ open · 2022Pooled it
- Effectiveness and Safety of Ayurvedic Medicines in Type 2 Diabetes Mellitus Management: A Systematic Review and Meta-Analysis.Frontiers in pharmacology · 2022Pooled it
- Effect of Nigella sativa-L supplementation on glycemia in adolescent polycystic ovarian syndrome: secondary analysis of a randomized controlled trial study.Journal of ovarian research · 2025Trial
- Evidence-Based Human Clinical Trials on Antidiabetic Herbal Remedies Commonly Used in the Middle East.Sultan Qaboos University medical journal · 2025Review
- Assessing the efficacy of herbal supplements for managing obesity: A comprehensive review of global clinical trials.Iranian journal of basic medical sciences · 2025Review
- The Use ofBiomedicines · 2024Review
- Comprehensive and updated review on anti-oxidant effects ofIranian journal of basic medical sciences · 2024Review
- LC-MS Metabolomic Profiling of Five Types of Unrefined, Cold-Pressed Seed Oils to Identify Markers to Determine Oil Authenticity and to Test for Oil Adulteration.Molecules (Basel, Switzerland) · 2023Article
- Effect ofCurrent issues in molecular biology · 2023Review
- The Effectiveness ofVascular health and risk management · 2023Article
- Mechanism of the antidiabetic action ofFrontiers in nutrition · 2023Review
- Complementary and alternative medicine for glycemic control of diabetes mellitus: A systematic review.Journal of public health research · 2022Review
- Potential health benefits ofFrontiers in nutrition · 2022Review
- IsVascular health and risk management · 2022Review
- Antidiabetic Activity ofChonnam medical journal · 2021Review
- Recent Progress on Chemical Constituents and Pharmacological Effects of the GenusEvidence-based complementary and alternative medicine : eCAM · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeNature is a phenomenal treasure of remedies. Numerous previous studies reported that Nigella sativa NS improved glycemic control, reduced insulin resistance, and improved lipid profile. NS was never investigated before as a monotherapy for newly diagnosed type 2 diabetes mellitus T2DM patients. Our aim was to investigate the potential metabolic benefits of NS monotherapy in newly diagnosed T2DM patients.
methodProspective, open-label randomized clinical trial at outpatient endocrinology clinic at Ain-Shams University hospital. Eligible patients were randomly assigned to either metformin tablets or NS oil capsules. Both groups received treatment for 3 months. Glycemic index (FBG, 2 h pp, A1C, insulin sensitivity %S, secretory function %B, insulin resistance IR), lipid profile (TC, LDL, HDL, TG), liver and kidney functions (AST, ALT, Sr cr), total antioxidant capacity TAC, weight, waist circumference WC and body mass index BMI were assessed at baseline and at the end of treatment period.
resultsA concentration of 1350 mg/day NS in newly diagnosed T2DM patients was inferior to metformin in terms of lowering FBG, 2 h pp, and A1C or increasing %B. However, NS was comparable to metformin in lowering weight, WC, and BMI significantly. NS was comparable to metformin in regards of their effects on fasting insulin, %S, IR, ALT, TC, LDL, HDL, TG, and TAC. Metformin showed significant increase in AST and creatinine which was reserved in NS group.
conclusionNS administration in newly diagnosed T2DM was tolerable with no side effects as compared to metformin; however, it was inferior to metformin in terms of diabetes management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.